Skorpios Trust
Known title: 10% OwnerCIK: 0001869333
Associated companies
Transaction History
| STOK | ▼ Sell | Open Market | 3,000,000 | $30.6M | 6/4/2025 | View on chart |
| STOK | ▼ Sell | Open Market | 2,000,000 | $23.0M | 12/23/2024 | View on chart |
| STOK | ▼ Sell | Open Market | 1,937,500 | $27.2M | 9/19/2024 | View on chart |
| STOK | ▼ Sell | Open Market | 3,600,000 | $41.8M | 4/17/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Stoke Therapeutics presents STK-002 data at AAO 2026 meeting
Stoke Therapeutics presented new data on its investigational drug STK-002 at the American Academy of Ophthalmology 2026 annual meeting. The data suggest the therapy may have disease-modifying potential for autosomal dominant optic atrophy. In a separate update, the company noted FDA alignment on endpoint criteria for its Zorevunersen program, which could affect future trial design.
Stoke Therapeutics presents STK-002 data at AAO 2026 meeting. Stoke Therapeutics presented new data on its investigational drug STK-002 at the American Academy of Ophthalmology 2026 annual meeting. The data suggest the therapy may have disease-modifying potential for autosomal dominant optic atrophy. In a separate update, the company noted FDA alignment on endpoint criteria for its Zorevunersen program, which could affect future trial design.